Anchored in technology developed by - and licensed from Univerity of Utah - GlycoMira is a development stage company developing semi-synthetic sulfated and alkylated derivatives of hyaluronan as potential anti-inflammatory products. With studies in animal models of inflammation completed, GlycoMira scientists synthesized a number of SAGE products, determined (through animal models) that SAGE products exhibit potent anti-inflammatory activity and would be patentable - plus that these products could have broad applications in human disease, GlycoMira filed patent applications and selected a common dermatological condition rosacea as an initial therapeutic target. Further to facilitate development of SAGE technology, GlycoMira entered into a licensing agreement with Brickell Biotech, Inc (BBI) under which terms BBI will develop the dermatological and ophthalmic uses of SAGE products. GlycoMira retained the core technology and all nondermatological topical and systemic uses of SAGE products. GlycoMira has determined that the best short-term potential target for its technology is topical treatment of gingivitis, periodontitis, and dental implantitis, and prevention of periodontal disease. A second short term target under investigation is the topical treatment of interstitial cystitis, a chronic inflammatory condition of the lining of the bladder
